Main menu

Oxford Nanopore Technologies announces new human health and disease study led by the UK National Institute for Health and Care Research (NIHR) BioResource


Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology, today announces its participation in a cohort study led by the UK National Institute for Health and Care Research (NIHR) BioResource to further explore human health and disease.

The study would involve using Oxford Nanopore’s platform to sequence up to 22,000 samples to further research in the initial areas of psychiatric, common and rare disease. Data would be made available to the scientific community through a managed access database hosted by the European Genome-phenome Archive (EGA) upon completion.

The NIHR BioResource is part of the NIHR and hosted by Cambridge University Hospitals NHS Foundation Trust (CUH) in partnership with the University of Cambridge and aligns with the UK government’s strategy to extend the UK’s leadership in genomic healthcare and research. This study will operate through a partnership between CUH and the University of Cambridge, with an additional partnership with King’s College London.

Researchers will use Oxford Nanopore’s high-throughput sequencing devices, the PromethION 48, which are uniquely designed to rapidly sequence large numbers of samples with high accuracy, delivering scalability for large projects.

The study is expected to start this year and complete in 2025.

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

纳米孔技术

订阅 Nanopore 更新 资源库及发表刊物 什么是 Nanopore 社区

关于 Oxford Nanopore

新闻 公司历程 可持续发展 领导团队 媒体资源和联系方式 投资者 合作者 在 Oxford Nanopore 工作 职位空缺 商业信息 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Chinese flag